Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.

G V Scagliotti, I Bondarenko, F Blackhall, F Barlesi, T-C Hsia, J Jassem, J Milanowski, S Popat, J M Sanchez-Torres, S Novello, R J Benner, S Green, K Molpus, J-C Soria, F A Shepherd

    Research output: Contribution to journal › Article › peer-review

    Fingerprint

    Dive into the research topics of 'Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.'. Together they form a unique fingerprint.

    Pharmacology, Toxicology and Pharmaceutical Science